Curated News
By: NewsRamp Editorial Staff
July 07, 2025
Silo Pharma Nears Key Data Release for PTSD Treatment SPC-15
TLDR
- Silo Pharma's upcoming SPC-15 data could position investors ahead in a niche market with no new PTSD treatments in 25 years.
- Silo Pharma is conducting IND-enabling GLP-compliant toxicology and toxicokinetic testing for SPC-15, aiming for a Phase 1 trial by 2026.
- SPC-15's development by Silo Pharma offers hope for a novel PTSD treatment, potentially improving mental health care for millions worldwide.
- Silo Pharma's intranasal SPC-15 could revolutionize PTSD treatment, marking a significant leap in mental health therapeutics after decades of stagnation.
Impact - Why it Matters
This news is significant because it highlights a potential breakthrough in the treatment of PTSD, a condition that affects millions worldwide and has seen limited therapeutic advancements in recent decades. Silo Pharma's innovative approach could offer a much-needed solution for individuals suffering from stress-induced psychiatric disorders, marking a pivotal moment in mental health treatment. The expedited development pathway underscores the urgency and importance of addressing PTSD, offering hope for faster access to effective treatments.
Summary
Silo Pharma (NASDAQ: SILO), a developmental-stage biopharmaceutical company, is on the brink of a significant milestone with its lead candidate SPC-15, an intranasal prophylactic aimed at enhancing stress resilience and preventing Post-Traumatic Stress Disorder (PTSD). The company anticipates data from two pivotal preclinical studies within the next 30 to 90 days. These studies, including IND-enabling GLP-compliant toxicology and toxicokinetic testing, along with a large animal safety study requested by the FDA, are crucial steps toward submitting an Investigational New Drug (IND) application. Silo Pharma is leveraging the FDA's 505(b)(2) pathway to accelerate the development of SPC-15, a novel approach in a field that hasn't seen new FDA drug approvals for PTSD in nearly a quarter of a century. For more details, visit the full press release.
Silo Pharma's innovative pipeline also includes SP-26, a time-release, ketamine-loaded implant for fibromyalgia and chronic pain relief, and two preclinical programs: SPC-14 for Alzheimer's disease and SPU-16 for multiple sclerosis. Collaborations with universities and independent laboratories underscore the company's commitment to addressing underserved conditions in stress-induced psychiatric disorders, chronic pain, and CNS diseases. Discover more about Silo Pharma's groundbreaking work at www.SiloPharma.com.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Silo Pharma Nears Key Data Release for PTSD Treatment SPC-15
